The earliest tested immunotherapy for NF1-associated tumors was imatinib mesylate, a C-Kit receptor tyrosine kinase inhibitor targeting mast-tumor cell signaling, for the treatment of plexiform neurofibromas. The gene discussed is NF1; the disease is plexiform neurofibroma.